Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 679 Carcinoma, Non-Small-Cell Lung 324 Neoplasms 168 Breast Neoplasms 163 Urinary Bladder Neoplasms 157 Lung Neoplasms 157 Neoplasm Metastasis 139 Cholangiocarcinoma 112 Ovarian Neoplasms 106 Biliary Tract Neoplasms 92 Lymphoma, Large B-Cell, Diffuse 73 Nasopharyngeal Carcinoma 70 Lymphoma 66 Sarcoma 63 Recurrence 62 Gallbladder Neoplasms 60 Carcinoma, Transitional Cell 55 Triple Negative Breast Neoplasms 54 Hodgkin Disease 52 Colorectal Neoplasms 49 Fallopian Tube Neoplasms 48 Lymphoma, Non-Hodgkin 47 Adenocarcinoma 45 Bile Duct Neoplasms 40 Carcinoma, Ovarian Epithelial 31 Non-Muscle Invasive Bladder Neoplasms 30 Uterine Cervical Neoplasms 28 Carcinoma 28 Unspecified Adult Solid Tumor, Protocol Specific 27 Adenocarcinoma of Lung 27

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × Gemcitabine × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡